Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Clovis Oncology, Inc is a biotechnology business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 484 staff and has a trailing 12-month revenue of around USD$159.4 million.
|Latest market close||USD$4.42|
|52-week range||USD$2.93 - USD$16.62|
|50-day moving average||USD$6.0085|
|200-day moving average||USD$6.7004|
|Wall St. target price||USD$9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-7.495|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-0.45%|
|1 month (2020-11-06)||3.76%|
|3 months (2020-09-04)||-14.17%|
|6 months (2020-06-05)||-33.83%|
|1 year (2019-12-05)||-50.11%|
|2 years (2018-12-04)||-77.89%|
|3 years (2017-12-05)||-92.34%|
|5 years (2015-12-04)||-86.98%|
Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$159.4 million|
|Gross profit TTM||USD$113.1 million|
|Return on assets TTM||-33.61%|
|Return on equity TTM||-547.55%|
|Market capitalisation||USD$504.5 million|
TTM: trailing 12 months
There are currently 39.2 million Clovis Oncology shares held short by investors – that's known as Clovis Oncology's "short interest". This figure is 3.3% up from 37.9 million last month.
There are a few different ways that this level of interest in shorting Clovis Oncology shares can be evaluated.
Clovis Oncology's "short interest ratio" (SIR) is the quantity of Clovis Oncology shares currently shorted divided by the average quantity of Clovis Oncology shares traded daily (recently around 5.3 million). Clovis Oncology's SIR currently stands at 7.35. In other words for every 100,000 Clovis Oncology shares traded daily on the market, roughly 7350 shares are currently held short.
However Clovis Oncology's short interest can also be evaluated against the total number of Clovis Oncology shares, or, against the total number of tradable Clovis Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Clovis Oncology's short interest could be expressed as 0.44% of the outstanding shares (for every 100,000 Clovis Oncology shares in existence, roughly 440 shares are currently held short) or 0.4571% of the tradable shares (for every 100,000 tradable Clovis Oncology shares, roughly 457 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Clovis Oncology.
Find out more about how you can short Clovis Oncology stock.
We're not expecting Clovis Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $2.93 up to $16.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 2.2339. This would suggest that Clovis Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.